Investigations into syndromic CMC have revealed insights, such as the role of IL-17A/F in safeguarding against Candida spp., in patients with specific genetic mutations such as dominant-negative signal transducer and activator of transcription 3 (STAT3), hyper-IgE syndrome, caspase recruitment domain-containing protein 9 (CARD9) deficiency, IL-12p40 deficiency, or IL-12Rβ1 deficiency. This evidence concerns the gene CARD9 and hyper-IgE syndrome.